EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular and Stroke Benefits
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.
#Stroke
1 story